PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-22.03%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-22.03%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-22.30%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-22.29%
Negative EPS growth while CRVO is at 0.00%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-22.29%
Negative diluted EPS growth while CRVO is at 0.00%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-72.30%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-72.45%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-22389.18%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
42.89%
Below 50% of CRVO's 97.71%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
64.68%
3Y OCF/share CAGR at 75-90% of CRVO's 81.67%. Bill Ackman would press for improvements in margin or overhead to catch up.
-7255.64%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-121.67%
Negative 5Y net income/share CAGR while CRVO is 99.71%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
22.78%
Below 50% of CRVO's 86.06%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
5223.15%
10Y equity/share CAGR above 1.5x CRVO's 677.85%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
855.06%
5Y equity/share CAGR above 1.5x CRVO's 100.32%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
-50.27%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
53.46%
Asset growth above 1.5x CRVO's 27.62%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
59.08%
BV/share growth of 59.08% while CRVO is zero. Bruce Berkowitz sees if small growth can compound into a strong advantage.
No Data
No Data available this quarter, please select a different quarter.
15.66%
R&D dropping or stable vs. CRVO's 59.83%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
40.35%
SG&A growth well above CRVO's 16.71%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.